Analysis of why Sunitinib (Sutent) is not recommended for some patients

Sunitinib (Sunitinib, trade nameSutent) is an oral multi-target tyrosine kinase inhibitor. Preparations are mainly used to treat renal clear cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) and some pancreatic neuroendocrine tumors. Its mechanism of action is to inhibit various receptor kinases such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), thereby preventing tumor angiogenesis and cell proliferation. However, sunitinib is not suitable for all patients, and some patients have contraindications or risks that need to be carefully evaluated.

Sunitinib should not be used in patients with severe cardiovascular disease. This drug may cause high blood pressure, heart failure, or arrhythmias, worsening underlying heart disease risks. In patients with cardiac insufficiency, recent myocardial infarction, or severe arrhythmias, the use of sunitinib without strict evaluation and monitoring may cause serious complications, so careful consideration or alternative treatment options are required.

It is also not recommended for patients with hepatic impairment or severe renal impairment. Sunitinib is mainly metabolized by the liver, and its metabolites are excreted by the kidneys. Abnormal liver and kidney function may lead to drug accumulation, thereby increasing toxic side effects such as hand-foot syndrome, gastrointestinal reactions, or hematological abnormalities. In such patients, sunitinib use may need to be reduced or avoided entirely to prevent serious adverse events.

Pregnant and lactating women are also not suitable to use sunitinib. The drug has been shown to have teratogenic effects on the fetus in animal experiments and may affect the infant via breast milk. Therefore, pregnant women need contraception, and lactating women should suspend breastfeeding or choose alternative treatments. In short, although sunitinib has significant efficacy, it has obvious risks in cardiovascular disease, abnormal liver and kidney function, and in pregnant and lactating people. Patients should conduct individualized assessment and medication selection under the guidance of professional doctors.

Reference materials:https://www.drugs.com/